Advances in drug therapy for primary biliary cholangitis
10.3969/j.issn.1001-5256.2020.01.053
- VernacularTitle:原发性胆汁性胆管炎的药物治疗进展
- Author:
Juan HAO
1
;
Jing LYU
;
Feng XING
Author Information
1. Shanghai Integrated Traditional Chinese and Western Medical Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200082, China
- Publication Type:Research Article
- Keywords:
liver cirrhosis, biliary;
drug therapy;
TCM WM therapy
- From:
Journal of Clinical Hepatology
2020;36(1):222-226
- CountryChina
- Language:Chinese
-
Abstract:
Primary biliary cholangitis (PBC) is a cholestatic liver disease with unclear etiology and pathogenesis. Ursodeoxycholic acid and obeticholic acid are the therapeutic drugs for PBC approved by the US Food and Drug Administration, both of which have the effect of alleviating intrahepatic cholestasis. However, some patients still have poor biochemical response to them, and it is urgent to explore new therapeutic drugs or methods. Fibrates, immunosuppressants, and traditional Chinese medicine have a certain effect in the treatment of patients with PBC, but further studies are needed to analyze their clinical safety and mechanism of action.
